...
首页> 外文期刊>BMC Psychiatry >EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome
【24h】

EXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome

机译:说明Fragile-X:有关脆性X综合征的特征,治疗途径和患者相关结果的探索性纵向研究

获取原文
           

摘要

Background Fragile X syndrome (FXS), caused by a mutation of the FMR1 gene on the X chromosome, is the most common inherited form of intellectual disability and autism spectrum disorders. Comprehensive data are lacking, however, on the characteristics and management patients with FXS in Germany. Methods/design EXPLAIN is a prospective, observational, longitudinal registry with a non-probability sampling approach. It collects data on patient characteristics, therapeutic interventions, psychosocial parameters (including those of family members and caregivers), quality of life of caregiver and patient, caregiver burden, and health economic parameters, such as hospitalisation time. It is designed to include data from 300 patients in ambulatory care from about 50 centres that employ psychiatrists, paediatricians, neurologists, and other relevant specialists, in Germany. The study was initiated in March, 2013. Patients will be followed for at least two years. Discussion The registry is expected to provide much-needed data on the characteristics and management of patients with FXS in Germany. It will also allow comparisons with other countries, and will enable gap analyses based on current guidelines for management of these patients. Trial registration The ClinicalTrials.gov identifier is NCT01711606 .
机译:背景X染色体上的FMR1基因突变引起的脆性X综合征(FXS)是智力残疾和自闭症谱系障碍的最常见遗传形式。但是,缺乏关于德国FXS的特征和治疗患者的综合数据。方法/设计EXPLAIN是一种前瞻性,观察性,纵向登记册,采用非概率抽样方法。它收集有关患者特征,治疗干预措施,社会心理参数(包括家庭成员和照顾者的心理社会参数),照顾者和患者的生活质量,照顾者负担以及健康经济参数(例如住院时间)的数据。它旨在包括来自德国约50个中心的雇用精神病学家,儿科医生,神经病学家和其他相关专家的300个门诊医疗患者的数据。该研究于2013年3月开始。将对患者进行至少两年的随访。讨论预计该注册表将提供有关德国FXS患者特征和管理的急需数据。它还将允许与其他国家进行比较,并将根据当前针对这些患者的治疗指南进行差距分析。试验注册ClinicalTrials.gov的标识符为NCT01711606。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号